<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018170</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-FRC-101</org_study_id>
    <nct_id>NCT04018170</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase I Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of JW1601</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the safety/tolerability and PK/PD of JW1601 after oral
      administration in healthy Korean, Caucasian and Japanese adult volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose block-randomized, double-blind, placebo-controlled, single and multiple
      ascending dose study to assess the safety, tolerability and PK/PD profile by administering
      investigational product (IP) as a single dose (One time) or repeated doses (7 days, once a
      day) orally in a fasted state.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability after single ascending dose administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring</measure>
    <time_frame>From Day 1 through Post Study Visit (Day 8)</time_frame>
    <description>AE incidence and the value or the change from baseline such as vital signs, 12-lead ECG, and clinical laboratory tests will be compared by each group and placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability in multiple ascending dose administration based on laboratory values, vital signs, ECG, physical examinations and Adverse Events monitoring</measure>
    <time_frame>From Day 1 through Post Study Visit (Day 14)</time_frame>
    <description>AE incidence and the value or the change from baseline such as vital signs, 12-lead ECG, and clinical laboratory tests will be compared by each group and placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax in plasma in single ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 4</time_frame>
    <description>Maximum concentration of drug in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in plasma in single ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 4</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast in plasma in single ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 4</time_frame>
    <description>Area under the plasma drug concentration-time curve to last measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil shape change(%) in single ascending dose administration</measure>
    <time_frame>Baseline(Day -1) through Day 4</time_frame>
    <description>Imetit-induced eosinophil shape change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT/QTc changes in single ascending dose administration</measure>
    <time_frame>Baseline(Day -1), Day 1, Day 2</time_frame>
    <description>12-lead ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(max, ss) in plasma in multiple ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 10</time_frame>
    <description>Maximum concentration of drug in plasma (at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T(max,ss) in plasma in multiple ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 10</time_frame>
    <description>Time to maximum plasma concentration (at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(τ,ss) in plasma in multiple ascending dose administration</measure>
    <time_frame>Baseline(Day 1) through Day 10</time_frame>
    <description>Area under the plasma drug concentration-time curve within a dosing interval(τ) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil shape change(%) in multiple ascending dose administration</measure>
    <time_frame>Baseline(Day -1) through Day 10</time_frame>
    <description>Imetit-induced eosinophil shape change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT/QTc changes in multiple ascending dose administration</measure>
    <time_frame>Baseline(Day -1), Day 7, Day 8</time_frame>
    <description>12-lead ECG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>JW1601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet formulation identified with JW1601</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study drug</intervention_name>
    <description>oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg</description>
    <arm_group_label>JW1601</arm_group_label>
    <other_name>JW1601</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Subjects who have voluntarily given written informed consent to participate in the study
        and comply with all study requirements after getting detailed explanation and full
        understanding of the study

        Exclusion Criteria:

        - Subjects judged by the investigators unsuitable for participating in the study based on
        any other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minsoo Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06725</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

